Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21499689 | 0.94 | PDE5A (0.41) | P2RX3TRPC5KCNH2TRPC4TP53 | |
| SCHEMBL21499690 | 0.92 | P2RX3 (0.39) | P2RX3TRPC5KCNH2TRPC4TP53 | |
| SCHEMBL21316298 | 0.89 | P2RX3 (0.46) | P2RX3TRPC5TP53PDE5A | |
| SCHEMBL19505090 | 0.86 | TSHR (0.40) | P2RX3TP53PDE5ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21499648 | 0.85 | TRPC4 (0.40) | P2RX3TRPC5KCNH2TRPC4TP53 | |
| SCHEMBL19375035 | 0.84 | P2RX3 (0.44) | P2RX3 | |
| SCHEMBL19505259 | 0.84 | P2RX3 (0.39) | P2RX3TRPC5KCNH2TRPC4TP53 | |
| SCHEMBL20432348 | 0.83 | P2RX3 (0.40) | P2RX3TRPC5KCNH2TRPC4TP53 | |
| SCHEMBL18834916 | 0.83 | TRPC4 (0.45) | P2RX3TRPC5KCNH2TRPC4 | |
| SCHEMBL19374881 | 0.83 | P2RX3 (0.44) | P2RX3TRPC5KCNH2TRPC4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399982-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2970303-B3 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2970303-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399982-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | P2RX3 30/4885TRPC5 1/4885KCNH2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.